Lumexa Imaging Holdings, Inc. (LMRI)
| Market Cap | 768.65M |
| Revenue (ttm) | 1.03B +10.1% |
| Net Income | -37.70M |
| EPS | -0.49 |
| Shares Out | 96.08M |
| PE Ratio | n/a |
| Forward PE | 9.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 644,293 |
| Open | 8.41 |
| Previous Close | 8.18 |
| Day's Range | 7.99 - 8.64 |
| 52-Week Range | 6.45 - 19.45 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 18.00 (+125.0%) |
| Earnings Date | May 12, 2026 |
About LMRI
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.
Financial Performance
In 2025, Lumexa Imaging Holdings's revenue was $1.02 billion, an increase of 7.82% compared to the previous year's $948.87 million. Losses were -$47.10 million, -49.94% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LMRI stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 125.00% from the latest price.
News
Lumexa Imaging price target lowered to $9 from $15 at Barclays
Barclays lowered the firm’s price target on Lumexa Imaging (LMRI) to $9 from $15 and keeps an Overweight rating on the shares. The firm says RadNet is outperforming Lumexa on…
Lumexa Imaging director buys 30K shares of common stock
In a regulatory filing, Lumexa Imaging (LMRI) disclosed that its director, Henry Cooper, bought 30K shares of common stock on May 14th in a total transaction size of $223K. Shares…
Lumexa Imaging Q1 Earnings Call Highlights
Lumexa Imaging NASDAQ: LMRI reported first-quarter results that management said were in line with expectations, as growth in advanced imaging modalities helped offset seasonal volume pressure and weat...
Lumexa Imaging Holdings Earnings Call Transcript: Q1 2026
Q1 revenue grew 3% year-over-year to $253 million, with advanced modalities driving 7% volume growth and PET up 23%. Adjusted EBITDA was flat at $51.2 million, impacted by weather and seasonality, but guidance for 2026 remains strong with expected ramp in the second half.
Lumexa Imaging Holdings Earnings release: Q1 2026
Lumexa Imaging Holdings released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Lumexa Imaging Holdings Quarterly report: Q1 2026
Lumexa Imaging Holdings has published its Q1 2026 quarterly earnings report on May 12, 2026.
Lumexa Imaging Announces First Quarter 2026 Results
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced results for the first quarter ended...
Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced the addition of four new locations ...
Lumexa Imaging Announces First Quarter 2026 Earnings Conference Call Date
RALEIGH, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced it will release its first quarter...
Lumexa Imaging Holdings Proxy statement: Proxy filing
Lumexa Imaging Holdings filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Lumexa Imaging Holdings Proxy statement: Proxy filing
Lumexa Imaging Holdings filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Lumexa Imaging appoints Lynch as Chief Growth Officer
Lumexa Imaging (LMRI) announced the appointment of Kyle Lynch as its new Chief Growth Officer, CGO. Lynch joins the executive leadership team to lead the company’s enterprise growth strategy, with…
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging's platform Proven healthcare growth leader to drive disciplined, profitable expansion and sca...
Lumexa Imaging price target lowered to $15 from $23 at Barclays
Barclays lowered the firm’s price target on Lumexa Imaging (LMRI) to $15 from $23 and keeps an Overweight rating on the shares after meeting with management. The company reiterated its…
Lumexa Imaging price target lowered to $17 from $23 at Raymond James
Raymond James lowered the firm’s price target on Lumexa Imaging (LMRI) to $17 from $23 and keeps a Strong Buy rating on the shares following Q4 earnings. The firm notes…
Lumexa Imaging Holdings, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI). The investigation focuses o...
Lumexa Imaging Holdings Inc trading resumes
09:39 EDT Lumexa Imaging (LMRI) Holdings Inc trading resumes
Lumexa Imaging Holdings Inc trading halted, volatility trading pause
09:34 EDT Lumexa Imaging (LMRI) Holdings Inc trading halted, volatility trading pause
Lumexa Imaging Holdings Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year 2025 growth, driven by advanced imaging, new center openings, and technology adoption. 2026 guidance reaffirms revenue and EBITDA growth, with continued focus on advanced modalities, geographic expansion, and operational efficiency.
Lumexa Imaging Holdings Annual report: Q4 2025
Lumexa Imaging Holdings has published its Q4 2025 annual report on March 26, 2026.
Lumexa Imaging Holdings Earnings release: Q4 2025
Lumexa Imaging Holdings released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Lumexa Imaging Holdings Slides: Investor presentation
Lumexa Imaging Holdings has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance
RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced certain financial results for the...
Lumexa Imaging Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Outpatient imaging growth is driven by advanced modalities, technology investments, and targeted de novo expansion. Strong commercial payer mix, transparent JV reporting, and AI-driven workflow improvements support financial performance and capacity growth.
Lumexa Imaging Holdings Transcript: 47th Annual Raymond James Institutional Investor Conference
Radiology is seeing rapid growth and consolidation, with advanced imaging driving revenue and margin expansion. The company leverages JV partnerships, de novo openings, and a strong commercial payer mix to fuel growth, while maintaining high patient satisfaction and transparent financial reporting.